Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults. It was developed and is marketed by Gilead Sciences with the brand name Emtriva.

	Results from FactBites:
	Emtricitabine - Wikipedia, the free encyclopedia (477 words) Emtricitabine (FTC), with trade name Emtriva® (formerly Coviracil), is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults. Emtricitabine was discovered by Dr. Dennis Liotta, Dr. Raymond Schinazi and Dr. Woo-Baeg Choi of Emory University and licensed to Triangle Pharmaceuticals by Emory in 1996. Emtricitabine is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva Online, Description, Chemistry, Ingredients - Emtricitabine - RxList Monographs (709 words) Emtricitabine is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position. Emtricitabine is a white to off-white powder with a solubility of approximately 112 mg/mL in water at 25 Emtricitabine, a synthetic nucleoside analog of cytosine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate.
	More results at FactBites »